Patients with relapsed chronic lymphocytic leukemia who were treated with either limited or continuous venetoclax and rituximab experienced improved responses during a 5-year follow-up.
A phase 2 study found that acalabrutinib monotherapy followed by treatment with venetoclax and obinutuzumab in the frontline setting was highly active and tolerable for patients with previously untreated chronic lymphocytic leukemia despite not meeting the primary end point.
In a debate, experts discuss the importance of IGHV and TP53 mutational status in predicting response to novel therapies in chronic lymphocytic leukemia.
Ibrutinib for treating patients with chronic lymphocytic leukemia increased the risk of atrial fibrillation, bleeding, and heart failure in results of a cohort study.
As more novel therapeutic targets are discovered in patients with chronic lymphocytic leukemia, the more possibilities are presented in terms of treatment with targeted agents, small molecules, and cellular therapies.
Patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma appeared to benefit from treatment with pirtobrutinib.
Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma were pretreated with ibrutinib saw a reduction in obinutuzumab-induced infusion-related reactions as well as cytokines and chemokines.
A systemic review and network meta-analysis investigated 3 trials and determined that acalabrutinib/obinutuzumab up front prolongs progression-free survival for patients with chronic lymphocytic leukemia vs other regimens.
The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.